Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
David McKillips, President and CEO of CEC Entertainment, discusses the ongoing Chuck E. Cheese brand refresh, new locations, updated play spaces and more.
Lila MacLellan, Senior Writer at Fortune, discusses how the healthcare industry is reacting to the murder of United Healthcare CEO Brian Thompson. Watch!
Matt Hougan from Bitwise Asset Management joins Cheddar to discuss how and why Bitcoin is continuing to rise and what the future holds for the cryptocurrency.
Should real estate agents fear AI? Tushar Garg CEO at Flyhomes says no. He joined Cheddar to discuss the future of AI in the Real Estate business and more.
Christopher Zara, Senior Editor at Fast Company joined Cheddar to discuss the newly formed "DOGE"’s new goal to cut 2-trillion dollars from federal spending.
